Semaglutide 2.4 mg injection (Wegovy , Novo Nordisk ), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved in June 2021 for chronic weight management in adults with overweight and 1 weight-related condition or obesity based on demonstrated weight reduction in clinical trials [10]
Why once weekly
Youll be able to choose from two types of compounded GLP-1 medications: Compounded Semaglutide Compounded Tirzepatide We have true month-to-month plans - pay as you go, refill when youre ready
To that point, the use of nonprescription weight loss products in young people has been linked to an increased risk of eating disorders, low self esteem, depression, poor nutritional intake, and substance use, according to a JAMA Network Open report
These treatments work best alongside nutrition guidance and regular activity not as a standalone fix
H.MillerH